Iridex Corporation announced the publication of a landmark five-year peer-reviewed study in Ophthalmology Therapy. This study confirms the sustained safety and efficacy of MicroPulse Transscleral Laser Therapy (TLT) for managing both primary and secondary glaucoma.
Conducted by Dr. Ronald de Crom and colleagues at the University Eye Clinic Maastricht, Netherlands, the research assessed 165 eyes, with 112 completing the five-year follow-up, using the Iridex Cyclo G6® Laser in its MicroPulse® Mode. Results demonstrated significant intraocular pressure (IOP) reductions of 32.5% on average (p<0.001).
The study also showed a significant reduction in IOP-lowering medications (p<0.005) with a low complication rate across a broad range of glaucoma types and severities. Only 38% of eyes required retreatment over the five-year period, highlighting the repeatability and long-term benefits of the MicroPulse treatment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.